David Gerber, MD, on ALK-Positive NSCLC: Crizotinib vs Observation for Surgically Resected Early-Stage Disease

September 18, 2025 By The ASCO Post Staff

David Gerber, MD, of UT Southwestern Medical Center, reviews findings from the phase III E4512 trial, which evaluated the hypothesis that postoperative crizotinib may improve disease-free survival in patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), based on the drug’s efficacy and regulatory approval in advanced ALK-positive NSCLC (Abstract PL02.18). 

Related Content